Approximately 23%–28% of patients with advanced non–small cell lung cancer (NSCLC) have a high level of PD-L1 expression, defined as membranous PD-L1 expression on at least 50% of tumour cells, regardless of the staining intensity [1,4]. Here, CD274 is linked to neoplasm.